Key facts today
Eli Lilly's weight loss drug Zepbound has outpaced Novo Nordisk's Wegovy in U.S. prescriptions, enhancing its position in the obesity market. Lilly's retatrutide is in Phase 3 trials.
Eli Lilly plans a $5 billion facility in Virginia to produce active ingredients for cancer and autoimmune drugs. This is part of a $27 billion investment to boost U.S. manufacturing.
Eli Lilly will submit orforglipron for regulatory review this year, expecting a global launch next year. Clinical trials show an average weight loss of 12.4% in patients.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
12.8 EUR
10.23 B EUR
43.51 B EUR
848.59 M
About Eli Lilly and Company
Sector
Industry
CEO
David A. Ricks
Website
Headquarters
Indianapolis
Founded
1876
ISIN
US5324571083
FIGI
BBG00PKLKBY1
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Related stocks
Eli Lilly (LLY) Weekly Chart – Double Top Patterns & Major SuppoLLY has formed consecutive double top patterns within a broad descending channel.
Price recently tested a long-term major support zone and bounced strongly, signaling renewed buying interest. If this momentum holds, a move toward the major resistance near $973 is possible, aligning with the upper
$LLY: Decision Zone — Wedge Breakout or Retest of 685Eli Lilly (LLY) rebounded off the long-term trendline and weekly demand box (≈622–686) and is compressing inside a descending wedge.
Bullish path (blue): a clean break and retest of wedge resistance opens room toward the prior extension/marker near ~970.
Bearish path (red): rejection at the
Lilly Has Fallen. Can it Get Up?Eli Lilly has been trending lower, and some traders may see further downside risk in the pharma giant.
The first pattern on today’s chart is the bearish gap on August 7. The decline came despite better-than-expected quarterly results, which may reflect weakening fundamentals.
Second is the May 23
LLY - Clean Levels UpdatedEli Lilly's hit those 708.49 and 711 levels I mentioned in my previous LLY post.
I've added some weekly levels, and a couple relevant spots from my boxed LLY chart.
If LLY loses steam up here we could easily see a retest of that box top area in the $680 - $678 range. Otherwise if we see a market
LLY $720 Call Setup: Don’t Miss Out on This Breakout Play!🚀 LLY Weekly Options Analysis (2025-08-17) 🚀
### 🔎 Comprehensive Multi-Model Insights
**Grok/xAI Report**
* 📊 RSI: Neutral (Daily & Weekly \~46)
* 📈 Flow: Call/Put = **3.87 (Bullish bias)**
* 🔊 Volume: Weak vs. previous weeks → ⚠️ no strong institutional support
* 🛑 Trade: **No entry** (weak conf
LLY AUG-2025Eli Lilly ( NYSE:LLY ) rebounded strongly from the 640 support zone after institutional absorption. Price is now targeting the gap at 740, aligning with prior distribution levels. Sustained momentum above 700 could drive continuation into 737–740. Failure to hold above 640 risks a deeper move into t
Red Pill or Blue Pill?Red Pill first - let’s stick to some harsh realities, but using technical analysis only.
Why the harsh crash?
We were rejected at the Value Area high at $972, followed by another rejection at the 0.786 Fibonacci level at $916, along with the top of the flag pattern of this giant bull flag. This wa
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
LLY6003396
Eli Lilly and Company 5.5% 12-FEB-2055Yield to maturity
—
Maturity date
Feb 12, 2055
LLY6003092
Eli Lilly and Company 5.1% 12-FEB-2035Yield to maturity
—
Maturity date
Feb 12, 2035
LLY5750407
Eli Lilly and Company 4.5% 09-FEB-2027Yield to maturity
—
Maturity date
Feb 9, 2027
LLY6153505
Eli Lilly and Company FRN 15-OCT-2028Yield to maturity
—
Maturity date
Oct 15, 2028
LLY5750032
Eli Lilly and Company 5.1% 09-FEB-2064Yield to maturity
—
Maturity date
Feb 9, 2064
LLY5871809
Eli Lilly and Company 4.15% 14-AUG-2027Yield to maturity
—
Maturity date
Aug 14, 2027
LLY5547406
Eli Lilly and Company 5.0% 27-FEB-2026Yield to maturity
—
Maturity date
Feb 27, 2026
LLY6003479
Eli Lilly and Company 4.9% 12-FEB-2032Yield to maturity
—
Maturity date
Feb 12, 2032
LLY5750404
Eli Lilly and Company 4.5% 09-FEB-2029Yield to maturity
—
Maturity date
Feb 9, 2029
LLY4099975
Eli Lilly and Company 4.65% 15-JUN-2044Yield to maturity
—
Maturity date
Jun 15, 2044
LLY.GW
Eli Lilly and Company 5.55% 15-MAR-2037Yield to maturity
—
Maturity date
Mar 15, 2037
See all LLYC bonds
Curated watchlists where LLYC is featured.
Frequently Asked Questions
The current price of LLYC is 644.2 EUR — it has increased by 1.24% in the past 24 hours. Watch Eli Lilly and Company stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on VIE exchange Eli Lilly and Company stocks are traded under the ticker LLYC.
LLYC stock has risen by 2.53% compared to the previous week, the month change is a 8.82% rise, over the last year Eli Lilly and Company has showed a −23.10% decrease.
We've gathered analysts' opinions on Eli Lilly and Company future price: according to them, LLYC price has a max estimate of 1,011.61 EUR and a min estimate of 595.07 EUR. Watch LLYC chart and read a more detailed Eli Lilly and Company stock forecast: see what analysts think of Eli Lilly and Company and suggest that you do with its stocks.
LLYC reached its all-time high on Feb 27, 2025 with the price of 887.0 EUR, and its all-time low was 94.9 EUR and was reached on Jul 22, 2019. View more price dynamics on LLYC chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
LLYC stock is 1.96% volatile and has beta coefficient of 0.62. Track Eli Lilly and Company stock price on the chart and check out the list of the most volatile stocks — is Eli Lilly and Company there?
Today Eli Lilly and Company has the market capitalization of 601.98 B, it has increased by 4.78% over the last week.
Yes, you can track Eli Lilly and Company financials in yearly and quarterly reports right on TradingView.
Eli Lilly and Company is going to release the next earnings report on Oct 30, 2025. Keep track of upcoming events with our Earnings Calendar.
LLYC earnings for the last quarter are 5.36 EUR per share, whereas the estimation was 4.75 EUR resulting in a 12.70% surprise. The estimated earnings for the next quarter are 5.40 EUR per share. See more details about Eli Lilly and Company earnings.
Eli Lilly and Company revenue for the last quarter amounts to 13.21 B EUR, despite the estimated figure of 12.48 B EUR. In the next quarter, revenue is expected to reach 13.63 B EUR.
LLYC net income for the last quarter is 4.81 B EUR, while the quarter before that showed 2.55 B EUR of net income which accounts for 88.40% change. Track more Eli Lilly and Company financial stats to get the full picture.
Yes, LLYC dividends are paid quarterly. The last dividend per share was 1.28 EUR. As of today, Dividend Yield (TTM)% is 0.78%. Tracking Eli Lilly and Company dividends might help you take more informed decisions.
Eli Lilly and Company dividend yield was 0.67% in 2024, and payout ratio reached 44.39%. The year before the numbers were 0.78% and 77.91% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Sep 17, 2025, the company has 47 K employees. See our rating of the largest employees — is Eli Lilly and Company on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Eli Lilly and Company EBITDA is 20.66 B EUR, and current EBITDA margin is 41.75%. See more stats in Eli Lilly and Company financial statements.
Like other stocks, LLYC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Eli Lilly and Company stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Eli Lilly and Company technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Eli Lilly and Company stock shows the neutral signal. See more of Eli Lilly and Company technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.